Finally, a study showing decreased expression of the TSC2 gene product, tuberin, in sporadic squamous and basal cell carcinomas suggests that mTOR inhibitors may be useful in treating these common skin cancers as well [43]. This evidence concerns the gene MTOR and basal cell carcinoma.